These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32787376)

  • 21. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR; Ha KH; Lee K; Kim DJ
    PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.
    Kridin K; Amber K; Khamaisi M; Comaneshter D; Batat E; Cohen AD
    Immunol Res; 2018 Jun; 66(3):425-430. PubMed ID: 29855994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
    Ihana-Sugiyama N; Sugiyama T; Tanaka H; Ueki K; Kobayashi Y; Ohsugi M
    J Eval Clin Pract; 2020 Feb; 26(1):299-307. PubMed ID: 31161662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
    Chen CY; Wu VC; Lin CJ; Lin CS; Pan CF; Chen HH; Lin YF; Huang TM; Chen L; Wu CJ;
    Mayo Clin Proc; 2018 Dec; 93(12):1760-1774. PubMed ID: 30343892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study.
    Fisher A; Fralick M; Filion KB; Dell'Aniello S; Douros A; Tremblay É; Shah BR; Ronksley PE; Alessi-Severini S; Hu N; Bugden SC; Ernst P; Lix LM;
    Diabetes Obes Metab; 2020 Sep; 22(9):1648-1658. PubMed ID: 32383792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
    Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
    Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis.
    Chikata Y; Iwata H; Miyosawa K; Koike T; Yasuda H; Funamizu T; Doi S; Endo H; Wada H; Naito R; Ogita M; Dohi T; Kasai T; Isoda K; Okazaki S; Miyauchi K; Minamino T
    Sci Rep; 2022 Mar; 12(1):5129. PubMed ID: 35332212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH; Kim B; Choi H; Kim DJ; Kim HC
    Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
    Dicembrini I; Montereggi C; Nreu B; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2020 Jan; 159():107981. PubMed ID: 31870827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.
    Bouchi R; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Metab Res Rev; 2018 Feb; 34(2):. PubMed ID: 29054111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes.
    Chao CT; Wang J; Wu HY; Chien KL; Hung KY
    Oncotarget; 2017 Aug; 8(32):53028-53040. PubMed ID: 28881791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
    Yen FS; Chiang JH; Pan CW; Lin BJ; Wei JC; Hsu CC
    Diabetes Res Clin Pract; 2018 Jun; 140():279-287. PubMed ID: 29654814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.
    Bukvić Mokos Z; Petković M; Balić A; Marinović B
    Croat Med J; 2020 Apr; 61(2):93-99. PubMed ID: 32378375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor.
    Oba-Yamamoto C; Kameda H; Miyoshi H; Sekizaki T; Takase T; Yanagimachi T; Fujita Y; Nomoto H; Cho KY; Nakamura A; Nagai S; Atsumi T
    Intern Med; 2021; 60(15):2375-2383. PubMed ID: 34334589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
    Rai P; Zhao X; Sambamoorthi U
    J Pain Palliat Care Pharmacother; 2018; 32(2-3):90-97. PubMed ID: 30676844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents.
    Zullo AR; Duprey MS; Smith RJ; Gutman R; Berry SD; Munshi MN; Dore DD
    Diabetes Obes Metab; 2022 Feb; 24(2):247-256. PubMed ID: 34647409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of dipeptidyl peptidase-4 inhibitor in patients undergoing bypass surgery.
    Ogawa S; Okawa Y; Sawada K; Goto Y; Fukaya S; Suzuki T
    Asian Cardiovasc Thorac Ann; 2016 Nov; 24(9):863-867. PubMed ID: 27784818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.